8-K: Marker Therapeutics Secures $2 Million NIH Grant for Lymphoma Therapy Research

Marker Therapeutics has been awarded a $2 million grant from the National Institutes of Health to advance clinical trials of its MT-601 therapy for non-Hodgkin's lymphoma patients who have relapsed after CAR T-cell treatment.

Summary

• Marker Therapeutics has received a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program.
• The grant will support the clinical investigation of MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy.
• The funding is based on preliminary clinical data and non-clinical data demonstrating the anti-tumor activity of MT-601.
• The grant will support the Phase 1 APOLLO study, which is evaluating the safety and efficacy of MT-601 in relapsed NHL patients, including those previously treated with CAR-T therapy.
• The company has now received over $19 million in non-dilutive funding.
• The APOLLO trial is expected to enroll up to 30 participants across nine clinical sites in the United States during the dose escalation phase.

Sentiment

Score: 8

Explanation: The document is positive due to the significant grant award, encouraging preliminary clinical results, and the company's focus on non-dilutive funding. The company is addressing an unmet need in the market.

Positives

• The $2 million NIH grant provides non-dilutive funding, reducing the need for equity financing.
• The grant validates the potential of MT-601 and the APOLLO study.
• Preliminary results from the APOLLO study show objective responses in all three participants treated at City of Hope.
• No cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS) were observed in the preliminary results.
• The multiTAA-specific T cell platform is believed to be easier and less expensive to manufacture than genetically engineered T cell therapies.
• The company has a history of securing non-dilutive funding, demonstrating a commitment to financial responsibility.

Negatives

• The document does not explicitly mention any negatives.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of the clinical trials is not guaranteed, and there is a risk that the therapy may not be effective or safe.
• The company is dependent on continued non-dilutive funding to support its research and development activities.
• The company is still in the early stages of clinical development, and there is a risk that the therapy may not be approved by regulatory authorities.

Future Outlook

The company plans to continue the Phase 1 APOLLO study, monitor patients for long-term treatment effects, and apply for additional non-dilutive funding opportunities.

Management Comments

• Juan Vera, M.D., President and CEO of Marker Therapeutics, stated that the NIH grant will support their clinical Phase 1 study in CAR-relapsed patients with non-Hodgkins lymphoma.
• Dr. Vera believes the NIH decision suggests the potential scientific merit and the capacity of Markers APOLLO study to address an unmet medical need.
• Dr. Vera mentioned they are encouraged by the objective responses observed in all three study participants and the lack of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS).
• Dr. Vera stated that obtaining non-dilutive funding is an ongoing effort, and they are actively applying for additional opportunities.

Industry Context

The announcement is relevant to the immuno-oncology field, particularly in the development of T-cell therapies for hematological malignancies. The focus on patients who have relapsed after CAR T-cell therapy addresses a significant unmet need in the treatment of lymphoma.

Comparison to Industry Standards

• The company's multiTAA-specific T cell approach is differentiated from traditional CAR T-cell therapies by targeting multiple tumor antigens, potentially reducing the risk of tumor escape.
• The company's approach is also differentiated by not being genetically engineered, which may lead to easier and less expensive manufacturing.
• The company's focus on non-dilutive funding is a positive sign, as many biotech companies rely heavily on equity financing.
• The company's preliminary results showing objective responses in all three study participants are encouraging, but further data is needed to assess the long-term efficacy and safety of the therapy.
• Other companies in the space include Kite Pharma, Novartis, and Juno Therapeutics, which are developing CAR T-cell therapies. Marker's approach is different and may offer advantages in terms of safety and manufacturing.

Stakeholder Impact

• Shareholders will benefit from the non-dilutive funding and the potential for a successful therapy.
• Patients with relapsed NHL may benefit from a new treatment option.
• Employees may benefit from the company's growth and success.
• The company's success may attract further investment and partnerships.

Next Steps

• The company will continue the Phase 1 APOLLO study.
• The company will monitor patients for long-term treatment effects and durability of response.
• The company will apply for additional non-dilutive funding opportunities.

Key Dates

Keywords

Marker Therapeutics, MT-601, Non-Hodgkins Lymphoma, NHL, CAR T-cell therapy, NIH, SBIR, Immunotherapy, MultiTAA, APOLLO study, Clinical Trial, Oncology